Sinovac Biotech Ltd Stock Price, News & Analysis

SAIF Partners, holding approximately 15% of Sinovac Biotech Ltd. (SVA) shares, is urging shareholders to vote "FOR" their ten director candidates at the upcoming Special Meeting on July 8, 2025. The investment firm strongly criticizes the current Board's legitimacy and capabilities, highlighting concerns about their dividend distribution plans and governance practices.

SAIF Partners emphasizes several key issues, including the Board's failure to engage with management, lack of financial reasoning for proposed dividends, and inability to hire a new independent auditor following the resignation of the previous one in April. The firm believes the current Board proposed massive dividends merely to retain their positions without having the capability to deliver.

Shareholders are encouraged to use the GOLD proxy card to vote for Board changes, which SAIF Partners argues is necessary to restore credibility and unlock long-term value for all shareholders.

SAIF Partners, owning approximately 15% of Sinovac Biotech Ltd. (SVA), has issued a critical letter to shareholders regarding the upcoming Special Meeting of Shareholders on July 8, 2025. The letter challenges the current Board's recent announcement to pay "up to $138.73 per share" in total dividends, an increase from the previously announced $55 per share dividend.

SAIF Partners argues that the current Board's dividend promises are empty gestures made under pressure, highlighting that the previously announced $55 dividend was actually prepared by the former Board. The letter emphasizes several critical issues, including the resignation of Grant Thornton as independent auditor on April 21, 2025, ongoing legal battles preventing stock trading, and alleged unethical actions by the 1Globe and Orbimed group.

SAIF Partners has nominated ten new director candidates for election at the Special Meeting, including Sinovac's founder and current CEO. Their priorities include immediately distributing the $55 per share dividend, ending the six-year trading halt (currently at $6.47 per share), and implementing proper corporate governance.

SINOVAC Biotech Ltd. (NASDAQ: SVA) has issued a letter to shareholders urging them to vote "AGAINST" proposals at the upcoming July 9, 2025 Special Meeting that would remove the current Board and install what they term the "Reconstituted Imposter Former Board Slate." The current Board, installed following a January 2025 UK Privy Council ruling, has declared multiple significant dividends including a US$55.00 per share special cash dividend due July 7, 2025, and plans for additional dividends of US$11.00 and US$19.00 per share.

The Board has adopted a new dividend policy promising regular distributions of US$20.00 - US$50.00 per share from surplus cash. They are actively working to resume NASDAQ trading and exploring a potential Hong Kong Stock Exchange listing. The company is defending against legal challenges from the Dissenting Investor Group (Advantech/Prime Success and Vivo Capital) regarding dividend payments, having already prevailed in New York and Hong Kong courts.

The current Board criticizes the previous "Imposter Board" for failing to declare any dividends during their seven-year tenure while allegedly allowing insiders to receive over US$2 billion in dividends from the operating subsidiary and approving questionable transactions including an invalid PIPE deal and nearly US$100 million in investments in Vivo Capital Funds.

SINOVAC Biotech (NASDAQ: SVA) has secured a significant legal victory in Hong Kong against Advantech/Prime's lawsuit attempting to block a US$55.00 per common share special cash dividend. The Hong Kong High Court denied Advantech/Prime's petition for interim relief on June 27, 2025, ordering them to compensate SINOVAC's legal costs.

The ruling follows Advantech/Prime's failed petition in New York and clears another hurdle for the dividend distribution scheduled for July 7, 2025. The court criticized Advantech/Prime for failing to comply with disclosure duties and creating artificial urgency.

SINOVAC urges shareholders to vote by July 8 against proposals to remove the current Board and appoint what they term the "Reconstituted Imposter Former Board Slate."

SAIF Partners, owning 15% of Sinovac Biotech (SVA), has sent an open letter to shareholders criticizing the current Board's failure to act in shareholders' interests. The letter highlights the Board's inaction regarding dividend payments and resumption of share trading after a six-year halt, despite the company holding $10.3 billion in cash.

SAIF Partners has nominated ten new directors for election at the July 8, 2025 Special Meeting. The current four-member Board, dominated by 1Globe and OrbiMed representatives, is criticized for lacking legitimacy as most directors were not duly elected by shareholders or sanctioned by the Privy Council. SAIF Partners urges shareholders to vote the GOLD proxy card for their nominees, who commit to declaring significant dividends, resuming share trading, and resolving shareholder disputes.

SINOVAC Biotech (NASDAQ: SVA) has filed an investor presentation and launched www.VoteSinovac.com ahead of its Special Meeting on July 9, 2025. The Board is urging shareholders to vote "AGAINST" proposals to remove the current Board and appoint the Reconstituted Imposter Former Board Slate.

The current Board highlights its commitment to shareholders by promising up to $138.73 per common share in dividends, contrasting with the previous board's seven-year tenure without dividends. The Board emphasizes its efforts to protect shareholder rights, counter lawsuits from the Dissenting Investor Group (Advantech/Prime and Vivo Capital), and plans to explore a potential Hong Kong Stock Exchange listing.

The presentation criticizes the Dissenting Investor Group's track record, citing failed privatization attempts at below-market prices and self-dealing transactions. Shareholders must vote by July 8, 2025, with the Board recommending use of the WHITE proxy card to vote against both proposals.

Prime Success (8% shareholder of Sinovac Biotech) issued a statement regarding a New York court ruling that confirms their rights as shareholders, including voting rights at an upcoming Special Meeting. The court rejected the 1Globe Activist Board's attempts to prevent Prime Success from voting their shares. Prime Success emphasizes their $86 million PIPE investment was crucial for Sinovac's COVID vaccine development. They support immediate dividend distribution ($55.00 per share) and back SAIF Partners' director slate to end ongoing litigation, recruit new auditors, and resume NASDAQ trading. The dispute continues in arbitration at HKIAC, with Prime Success maintaining their right to return to NY court if their shareholder rights are challenged.

SINOVAC Biotech (NASDAQ: SVA) has won a significant legal victory against Advantech/Prime in the U.S. District Court for the Southern District of New York, which denied their petition for emergency injunctive relief. This ruling clears the way for SINOVAC to proceed with its planned special cash dividend of $55.00 per common share, scheduled for July 7, 2025. The company's current Board, led by Chairman Dr. Chiang Li, is also pursuing legal action in Antigua to cancel allegedly invalid PIPE shares issued to the Dissenting Investor Group. If successful, SINOVAC plans to distribute an additional $11.00 per share to valid shareholders. The company has placed the disputed dividend portions in escrow pending legal resolution. SINOVAC is urging shareholders to vote against proposals to remove the current Board and appoint a new slate by July 8.

SINOVAC Biotech (NASDAQ: SVA) has filed definitive proxy materials with the SEC for a Special Meeting of Shareholders scheduled for July 9, 2025. The Board is urging shareholders to vote AGAINST two key proposals using the WHITE proxy card: Proposal 1 to remove the current Board and Proposal 2 to appoint what they term the 'Reconstituted Imposter Former Board Slate.' The company is facing opposition from a Dissenting Investor Group led by Advantech/Prime Success and Vivo Capital, whom the current Board accuses of making false claims in a hostile takeover attempt. SINOVAC's Board emphasizes that shareholders' votes by July 8 will impact the company's future, including make whole dividend payments and long-term investment value. The company has appointed Georgeson LLC as their proxy solicitor to assist shareholders with voting matters.